Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management
Status:
Withdrawn
Trial end date:
2017-01-20
Target enrollment:
Participant gender:
Summary
Single arm, phase II exploratory trial to prospectively evaluate the impact of
68Ga-PSMA-PET/CT on the therapeutic management of patients with biological recurrent prostate
cancer and negative, equivocal or oligometastatic disease after routine imaging diagnostic
work-up.